M Dougados

Summary

Country: The Netherlands

Publications

  1. pmc Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment
    K Briot
    Hopital Cochin, Departement de Rhumatologie, 27 rue du Faubourg St Jacques, 75014 Paris, France
    Ann Rheum Dis 64:1137-40. 2005
  2. pmc Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
    L B A van de Putte
    University of Nijmegen, The Netherlands
    Ann Rheum Dis 63:508-16. 2004
  3. pmc Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study
    J F Maillefert
    Centre Hospitalier Universitaire Dijon, and INSERM ERIT M 0207, University of Burgundy, Dijon, France
    Ann Rheum Dis 62:764-6. 2003
  4. ncbi request reprint Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
    M C Genovese
    Stanford University, Division of Immunology and Rheumatology, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Ann Rheum Dis 67:547-54. 2008
  5. pmc Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
    J E Gottenberg
    Service de Rhumatologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 64:913-20. 2005
  6. pmc When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
    M Dougados
    Hopital Cochin, Rene Descartes University, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 64:44-51. 2005
  7. pmc Consensus statement on the use of rituximab in patients with rheumatoid arthritis
    J S Smolen
    Department of Rheumatology, Third Department of Internal Medicine, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:143-50. 2007
  8. ncbi request reprint Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
    A Ruyssen-Witrand
    Paris Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 25:430-6. 2007
  9. ncbi request reprint Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study
    N Assous
    Clin Exp Rheumatol 25:504. 2007
  10. pmc A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
    L Klareskog
    Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm 17176, Sweden
    Ann Rheum Dis 65:1578-84. 2006

Collaborators

Detail Information

Publications62

  1. pmc Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment
    K Briot
    Hopital Cochin, Departement de Rhumatologie, 27 rue du Faubourg St Jacques, 75014 Paris, France
    Ann Rheum Dis 64:1137-40. 2005
    ..To determine the changes in body weight, body composition, and bone turnover in patients with spondyloarthropathy (SpA) treated with anti-tumour necrosis factor alpha (TNFalpha)...
  2. pmc Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
    L B A van de Putte
    University of Nijmegen, The Netherlands
    Ann Rheum Dis 63:508-16. 2004
    ..To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed...
  3. pmc Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study
    J F Maillefert
    Centre Hospitalier Universitaire Dijon, and INSERM ERIT M 0207, University of Burgundy, Dijon, France
    Ann Rheum Dis 62:764-6. 2003
    ....
  4. ncbi request reprint Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
    M C Genovese
    Stanford University, Division of Immunology and Rheumatology, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Ann Rheum Dis 67:547-54. 2008
    ..To evaluate the safety and efficacy of abatacept during 2 years of the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trial in patients with rheumatoid arthritis...
  5. pmc Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
    J E Gottenberg
    Service de Rhumatologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 64:913-20. 2005
    ..To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice...
  6. pmc When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
    M Dougados
    Hopital Cochin, Rene Descartes University, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 64:44-51. 2005
    ..To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to leflunomide monotherapy...
  7. pmc Consensus statement on the use of rituximab in patients with rheumatoid arthritis
    J S Smolen
    Department of Rheumatology, Third Department of Internal Medicine, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:143-50. 2007
    ..The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis...
  8. ncbi request reprint Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
    A Ruyssen-Witrand
    Paris Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 25:430-6. 2007
    ..The aim of this study was to assess the complication rate after surgery in such patients, to assess the effect of interrupting TNF blocker therapy, and to identify other potential predictors of complications...
  9. ncbi request reprint Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study
    N Assous
    Clin Exp Rheumatol 25:504. 2007
  10. pmc A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
    L Klareskog
    Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm 17176, Sweden
    Ann Rheum Dis 65:1578-84. 2006
    ..To evaluate the long-term safety and efficacy of etanercept in patients with rheumatoid arthritis...
  11. pmc Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
    M Schiff
    Denver Arthritis Clinic, 200 Spruce Street 100, Denver, CO 80230, USA
    Ann Rheum Dis 67:1096-103. 2008
    ..The primary objective of this study was to evaluate the mean change from baseline in Disease Activity Score (based on erythrocyte sedimentation rates; DAS28 (ESR)) for the abatacept vs placebo groups at day 197...
  12. ncbi request reprint Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience
    C Richard-Miceli
    Clinique de Rhumatologie, , , , 27 rue du Fauborg Saint-Jacques, 75679 Paris Cedex 14, France
    BioDrugs 15:251-9. 2001
    ..This therapeutic response seems to be unequalled by "conventional" treatments in rheumatoid arthritis, and is incontestably a turning point in the therapeutic management of this disease...
  13. pmc An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis
    T Pham
    Department of Rheumatology, Aix Marseille II University, Conception Hospital, 147 Bd Baille, 13005 Marseille, France
    Ann Rheum Dis 65:1620-5. 2006
    ....
  14. ncbi request reprint Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up
    L Gossec
    Rheumatologie B, Hopital Cochin, 27 rue du Fbg St Jacques, 75014 Paris, France
    Rheumatology (Oxford) 45:859-62. 2006
    ..To evaluate the continuation and safety of treatment with infliximab in ankylosing spondylitis (AS) over a 2-yr period...
  15. pmc Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks
    J C Davis
    University of California, San Francisco, 533 Parnassus Ave Rm U 383 Box 0633, San Francisco, California, USA
    Ann Rheum Dis 64:1557-62. 2005
    ..To evaluate the continued safety and durability of clinical response in patients with ankylosing spondylitis receiving etanercept...
  16. pmc EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    B Combe
    Immuno Rhumatologie, Lapeyronie Hosp, Montpellier, France
    Ann Rheum Dis 66:34-45. 2007
    ..To formulate EULAR recommendations for the management of early arthritis...
  17. ncbi request reprint How to define a Minimal Clinically Individual State (MCIS) with pain VAS in daily practice for patients suffering from musculoskeletal disorders
    G Falgarone
    Paris Nord University, Avicenne Hospital AP HP, Rheumatology Department UPRES EA 3408, Bobigny, France
    Clin Exp Rheumatol 23:235-8. 2005
    ..The cut-offs permitting one to define both the entry criterion and the LDAS are not well established. The objective of this study was to evaluate such cut-offs using a patient-derived perspective...
  18. ncbi request reprint [Atherosclerosis and rheumatoid arthritis]
    M Soubrier
    Service de Rhumatologie, Hopital G Montpied, Place H Dunant, Clermont Ferrand, France
    Rev Med Interne 27:125-36. 2006
    ..To identify the different factors that may be involved. To consider what management would decrease the cardiovascular morbidity and mortality of RA...
  19. pmc First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 65:316-20. 2006
    ..To update the international recommendations for use of anti-tumour necrosis factor (TNF) agents in the treatment of ankylosing spondylitis...
  20. pmc Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis
    J Zochling
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 65:423-32. 2006
    ..To assess available management strategies in ankylosing spondylitis (AS) using a systematic approach, as a part of the development of evidence based recommendations for the management of AS...
  21. pmc Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
    D E Furst
    1000 Veteran Avenue Rehabilitation Centre, Room 32 59, Los Angeles, CA 90024, USA
    Ann Rheum Dis 64:iv2-14. 2005
  22. pmc Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review
    J Avouac
    Rene Descartes University, Medicine Faculty, and APHP Cochin Hospital, Rhumatologie B Department, Paris, France
    Ann Rheum Dis 65:845-51. 2006
    ....
  23. doi request reprint Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
    T Karonitsch
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1365-73. 2008
    ....
  24. doi request reprint Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1360-4. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  25. ncbi request reprint Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report
    S Guignard
    Paris 5 Medicine Faculty, Cochin Hospital, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 25:758-9. 2007
    ....
  26. ncbi request reprint Disease activity measures for rheumatoid arthritis
    M Dougados
    Hopital Cochin, Descartes University, Service de Rhumatologie B, Paris, France
    Clin Exp Rheumatol 25:S22-9. 2007
    ..Further studies are required to better evaluate the clinical relevance of methods for assessing disease activity in patients with RA...
  27. ncbi request reprint Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
    J C Davis
    University of California, San Francisco, 533 Parnassus Avenue, Box 0633, Room U 386, San Francisco, CA 94143 0633 USA
    Ann Rheum Dis 67:346-52. 2008
    ..Evaluate long-term safety and efficacy of etanercept treatment in patients with ankylosing spondylitis (AS)...
  28. ncbi request reprint Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients
    C Salliot
    Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Rheumatology (Oxford) 46:327-34. 2007
    ..To evaluate the rate of infections in rheumatic patients treated with tumour necrosis factor (TNF)-alpha blockers in daily practice and to determine potential risk factors of infections...
  29. pmc Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis
    D van der Heijde
    University Hospital Maastricht, Maastricht, The Netherlands
    Ann Rheum Dis 65:1572-7. 2006
    ..To compare the efficacy, pharmacokinetics and safety of etanercept 50 mg once weekly with 25 mg twice weekly and placebo in patients with ankylosing spondylitis...
  30. pmc Radiological damage in patients with rheumatoid arthritis on sustained remission
    G Cohen
    Immuno Rhumatologie, Montpellier I University, Centre Hospitalier Universitaire Lapeyronie, Montpellier, France
    Ann Rheum Dis 66:358-63. 2007
    ..To assess the radiological damage progression in patients with recent rheumatoid arthritis in sustained remission...
  31. pmc Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study
    S Guignard
    Rene Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 65:1631-4. 2006
    ..To evaluate the efficacy of anti-tumour necrosis factor (TNF) treatments (given for rheumatological manifestations) in reducing uveitis flares in patients with spondylarthropathy in daily practice...
  32. doi request reprint Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 59:1371-7. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  33. ncbi request reprint Leflunomide in rheumatoid arthritis in daily practice: treatment discontinuation rates in comparison with other DMARDs
    I Bettembourg-Brault
    Rheumatology B Department, Cochin Hospital, AP HP, Rene Descartes University, Paris, France
    Clin Exp Rheumatol 24:168-71. 2006
    ....
  34. pmc Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis
    L Gossec
    Hopital Cochin, Rhumatologie B, Paris, France
    Ann Rheum Dis 64:1563-7. 2005
    ..The combined efficacy of selective and non-selective cyclo-oxygenase-2 (COX-2) inhibition on the axial manifestations of ankylosing spondylitis (AS) in the presence or absence of chronic peripheral arthritis was evaluated...
  35. ncbi request reprint Benefit/risk of combination therapies
    D Zerkak
    Rheumatology B Department, Cochin Hospital, Rene Descartes University, Paris, France
    Clin Exp Rheumatol 22:S71-6. 2004
    ..In general, combinations appear safe and well-tolerated, but continued caution with appropriate monitoring of long-term results and possible toxicities is required...
  36. ncbi request reprint Arthroscopic evaluation of potential structure-modifying drug in osteoarthritis of the knee. A multicenter, randomized, double-blind comparison of tenidap sodium vs piroxicam
    X Ayral
    Service de Rhumatologie B, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Rene Descartes, Paris, France
    Osteoarthritis Cartilage 11:198-207. 2003
    ..To test the hypothesis that tenidap has a structure-modifying effect in human knee osteoarthritis...
  37. pmc Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage
    O Meyer
    Service de Rhumatologie, CHU Bichat, AP HP, Paris, France
    Ann Rheum Dis 62:120-6. 2003
    ..To study the value of antibodies to citrullinated proteins/peptides for predicting joint outcomes in patients with recent onset rheumatoid arthritis (RA)...
  38. ncbi request reprint Infliximab in spondylarthropathy--influence on bone density
    E Demis
    Rheumatology Department, Rene Descartes University, Cochin Hospital, Paris, France
    Clin Exp Rheumatol 20:S185-6. 2002
    ..There was an increase in osteocalcin between baseline and week 6. These data suggest a benefit of anti-TNFalpha therapy on BMD in patients with SpA, may be through an uncoupling effect on bone cells...
  39. ncbi request reprint Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial
    J Y Reginster
    Bone and Cartilage Unit, University of Liege, Liege, Belgium
    Osteoporos Int 13:925-31. 2002
    ..048). No effect on markers of bone resorption was observed. SR was as well tolerated as placebo. The minimum does at which SR is effective in preventing bone loss in early postmenopausal non-osteoporotic women is therefore 1 g/day...
  40. ncbi request reprint Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study
    M Breban
    Institut de Rhumatologie, Hopital Cochin, Universite Rene Descartes, Paris, France
    Rheumatology (Oxford) 41:1280-5. 2002
    ..To evaluate the efficacy and safety of a loading regimen of the anti-tumour necrosis factor alpha (TNF-alpha) antibody infliximab in predominantly axial severe ankylosing spondylitis (AS)...
  41. pmc Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis
    J F Maillefert
    Department of Rheumatology, Rene Descartes University, AP HP, Cochin Hospital, Paris, France
    Ann Rheum Dis 61:635-7. 2002
    ..Hepatitis C virus (HCV) infection, which has been recognised as a cause of some autoimmune diseases, and which has been described as sometimes presenting with rheumatic manifestations indistinguishable from RA, might be a candidate...
  42. pmc Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide
    P Emery
    Department of Rheumatology and Rehabilitation, University of Leeds School of Medicine, Leeds, UK
    Ann Rheum Dis 61:290-7. 2002
    ....
  43. ncbi request reprint Diacerein as a disease-modulating agent in osteoarthritis
    G Falgarone
    , Cochin Hospital, Rheumatology B Department, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Curr Rheumatol Rep 3:479-83. 2001
    ..However, clinical trials using new sets of criteria could be conducted to estimate the structural modulating effect of diacerein; experimental studies must be performed to understand this effect...
  44. ncbi request reprint Pharmacological therapy of osteoarthritis
    M C Hochberg
    Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, Maryland, 21201, USA
    Best Pract Res Clin Rheumatol 15:583-93. 2001
    ..The clinical relevance of such an effect needs to be further evaluated in long-term outcome studies...
  45. ncbi request reprint Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study
    J F Maillefert
    Department of Rheumatology, Dijon University Hospital, France
    Osteoporos Int 12:605-9. 2001
    ..1% +/- 5.7 and -1.2% +/- 3.9 in patients with and without persistent inflammation; respectively; p = 0.007). These results suggest that persistent inflammation might be an etiologic factor of bone loss in AS...
  46. ncbi request reprint Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study
    B Combe
    , Centre Hospitalier Universitaire Montpellier, and INSERM U475, France
    Arthritis Rheum 44:1736-43. 2001
    ..A combination of these baseline values allowed us to draw up a predictive arithmetic score that could be used to predict radiologic damage at 3 years and radiologic progression in individual patients...
  47. ncbi request reprint Disease controlling antirheumatic therapy in spondyloarthropathy
    M Dougados
    Department of Rheumatology, , Paris, France
    J Rheumatol Suppl 62:16-20. 2001
    ..Therapeutic efficacy is monitored chiefly according to clinical variables, although biochemical markers such as C reactive protein are also helpful...
  48. pmc Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha
    F Allali
    Rheumatology Department, Rene Descartes University, Cochin Hospital, Paris, France
    Ann Rheum Dis 62:347-9. 2003
    ..To determine the changes in bone mineral density (BMD) in patients with spondyloarthropathy (SpA) treated with infliximab...
  49. pmc Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries
    A Boonen
    Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, The Netherlands
    Ann Rheum Dis 62:732-40. 2003
    ..To assess direct costs associated with ankylosing spondylitis (AS). To determine which variables, including country, predict costs...
  50. pmc Paracetamol in osteoarthritis of the knee
    C Miceli-Richard
    Cochin Hospital, AP HP, Rene Descartes University, Paris, France
    Ann Rheum Dis 63:923-30. 2004
    ..Paracetamol is a recommended symptomatic treatment of osteoarthritis (OA), but in clinical trials sample sizes have been relatively small and variable daily doses of paracetamol have been used...
  51. ncbi request reprint DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets
    V Devauchelle
    Institut Cochin, Paris, France
    Genes Immun 5:597-608. 2004
    ..It is proposed that such an approach allows valuable diagnosis/prognostics tools in RA to be established and potential targets for combating the disease to be identified...
  52. pmc EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    W Zhang
    Academic Rheumatology, University of Nottingham, UK
    Ann Rheum Dis 64:669-81. 2005
    ..To develop evidence based recommendations for the management of hip osteoarthritis (OA)...
  53. pmc Detection of small joint synovitis by ultrasonography: the learning curve of rheumatologists
    M A D'Agostino
    Service de Rhumatologie B, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Ann Rheum Dis 63:1284-7. 2004
    ..Ultrasonography allows assessment of soft tissue structures and has become a valued tool for diagnosing synovitis...
  54. pmc Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis
    T Pham
    Conception Hospital, AP HM, Service de Rhumatologie Sud, Marseille, France
    Ann Rheum Dis 63:1611-7. 2004
    ..To evaluate long term efficacy of three iterative courses of three weekly intra-articular (IA) injections of NRD101 in the treatment of symptomatic knee osteoarthritis (OA)...
  55. ncbi request reprint HLA DRB1*01 and DRB1*04 phenotyping does not predict the need for joint surgery in rheumatoid arthritis. A retrospective quantitative evaluation of 300 French patients
    L Gossec
    Service de Rhumatologie B, Universite Rene Descartes, Centre Hospitalier Universitaire Cochin, Paris, France
    Clin Exp Rheumatol 22:462-4. 2004
    ..To determine if the presence of HLA-DR disease-associated epitopes predicts the need for total joint arthroplasty or joint fusion in rheumatoid arthritis (RA)...
  56. pmc Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study
    L Gossec
    Rene Descartes University, Cochin Hospital, Department of Rheumatology B, Paris, France
    Ann Rheum Dis 63:675-80. 2004
    ..To determine prognostic factors for remission in early rheumatoid arthritis...
  57. ncbi request reprint Combination therapy in early rheumatoid arthritis
    L Gossec
    Rene Descartes University, Cochin Hospital, Paris, France
    Clin Exp Rheumatol 21:S174-8. 2003
    ..It appears likely that the place of combination therapy will increase in the coming decades, even in very early RA patients, where the ultimate goal is persistent remission...
  58. ncbi request reprint Laterally elevated wedged insoles in the treatment of medial knee osteoarthritis. A two-year prospective randomized controlled study
    T Pham
    Rene Descartes University, Cochin Hospital, Paris, France
    Osteoarthritis Cartilage 12:46-55. 2004
    ..To compare the clinical effects of laterally wedged insoles and neutrally wedged insoles (used as control) in patients with medial femoro-tibial knee osteoarthritis...
  59. pmc Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)
    D E Furst
    University of California, UCLA, Rheumatology, Division Los Angeles, USA
    Ann Rheum Dis 62:ii2-9. 2003
  60. pmc International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Ann Rheum Dis 62:817-24. 2003
    ..To obtain an international consensus about the use of anti-tumour necrosis factor alpha (anti-TNF alpha) for treating patients with ankylosing spondylitis (AS)...
  61. pmc Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group
    T Pham
    Rene Descartes University, AP HP, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 62:812-6. 2003
    ..Moreover, studies suggest that anti-TNF could be considered as the first disease controlling antirheumatic treatment (DC-ART) for AS...
  62. ncbi request reprint [Pericardial and myocardial adiastole in rheumatoid polyarthritis]
    D Erciyes
    Service des maladies cardiovasculaires, , Paris
    Arch Mal Coeur Vaiss 92:1381-4. 1999
    ..The authors underline the involvement of the three cardiac tunics in rheumatoid arthritis and the value of different diagnostic methods in the differentiation between constrictive pericarditis and restrictive cardiomyopathy...